Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

• Drug: moroctocog alfa (AF-CC)
  
  Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
• Drug: moroctocog alfa (AF-CC)
  
  Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)

• Experimental: Sequence 1
  
  Subjects randomized to receive Treatment A during Period 1, then Treatment B during Period 2.
  Intervention: Drug: moroctocog alfa (AF-CC)
• Experimental: Sequence 2
  
  Subjects randomized to receive Treatment B during Period 1, then Treatment B during Period 2.
  Intervention: Drug: moroctocog alfa (AF-CC)

Inclusion Criteria:

• Male patients at least 18 years old with severe or moderately severe hemophilia A (facto VIII concentration less than or equal to 2%).
• Negative test for facto VIII inhibitor.
• If applicable, HIV or hepatitis treatment is stable at the time of enrollment.
• Ability to abstain from use of FVIII products for 72 hours at a time.

Exclusion Criteria:

• History of any positive test result for factor VIII inhibitor.
• Presence of any bleeding disorder in addition to Hemophilia A.
• Body weight less than 50 kg.
• History of alcoholism.
• Treatment with investigational drug or device within 30 days prior to the Screening visit.